Warning Signs

What this page covers

This page collects the warning signs that published trials and FDA documents link to commonly used peptides, along with what drug labels and users report. It's grouped by compound class because the signals differ between classes.

The quality of the evidence differs just as much. Semaglutide (Wegovy) and bremelanotide (Vyleesi) are prescription medicines whose labels rest on controlled trials, so they can say how often a problem happened compared with placebo. Research-use peptides like CJC-1295 or melanotan II have no label. What's known about them comes from small early trials and FDA safety reviews, with case reports filling gaps; those rarely show how often a problem happens or whether the peptide caused it.

Two more detailed articles sit under this one. Recognizing adverse reactions covers how reactions usually present and how they're graded by severity, including the symptoms labels treat as emergencies. When to discontinue peptides collects the stopping rules written into drug labels, such as suspected pancreatitis on GLP-1 drugs, plus what users report after stopping.

Growth hormone secretagogues and GHRH analogues

The best-documented drug in this group is tesamorelin, a GHRH analogue sold as Egrifta to reduce abdominal fat in adults with HIV-associated lipodystrophy. Its US label (Egrifta SV, revised February 2024) ties fluid retention to the rise in growth hormone. That shows up as swelling (edema) or joint pain, sometimes as carpal tunnel syndrome, and the label says these effects passed on their own or after treatment stopped. The label also warns that glucose intolerance or diabetes may develop.

The longest controlled trial of an oral secretagogue gave MK-677 (ibutamoren) at 25 mg a day to 65 healthy adults aged 60 to 81, with a second year of exploratory follow-up (Annals of Internal Medicine, 2008). Fasting glucose rose by an average of 5 mg/dL and insulin sensitivity fell. Appetite went up in 67% of MK-677 recipients versus 36% on placebo, usually settling within a few months. Mild, transient edema (44% vs 27%) and muscle pain (33% vs 9%) were the other common complaints. Joint pain was reported more often on placebo. Even so, four people on MK-677 had their dose cut to 10 mg a day: two because fasting glucose climbed and two because of joint pain. A separate trial in older adults recovering from hip fracture was stopped early over a safety signal of congestive heart failure.

In 2024, FDA's Pharmacy Compounding Advisory Committee (PCAC) voted against letting pharmacies compound CJC-1295 or ipamorelin. FDA's safety presentations there summarize the human data:

• CJC-1295 (December 2024 meeting): in the first dose-finding study in healthy adults, 94% of participants reported an adverse event after a single injection, and about 70% of those given the DAC form had injection-site reactions that were worse at higher doses. Other studies added flushing and low blood pressure, plus a faster heart rate. FDA also cited unpublished, anecdotal reports of a Phase 2 trial ended after a participant's fatal heart attack, which the attending physician blamed on undiagnosed coronary disease. The 2006 paper itself reported no serious adverse reactions.
• Ipamorelin (October 2024 meeting): FDA found no safety data for subcutaneous use, the route users describe. In an intravenous trial after bowel surgery, the ipamorelin group had more low potassium and high blood sugar at discharge, along with more insomnia and two deaths whose link to the drug was unclear.

FDA's compounding safety-risk list adds rising blood glucose for GHRP-2 and GHRP-6, without established causality.

Users of CJC-1295 and ipamorelin on Reddit commonly describe water retention and numb or tingling hands. On this point user reports and trial data agree. Rising glucose usually causes no symptoms; trials caught it with blood tests, which the blood work schedule page covers.

GLP-1 medicines

The Wegovy label (revised June 2026) carries a boxed warning about thyroid C-cell tumors, which appeared in rodent studies; whether this happens in people is unknown. Its Medication Guide names a lump or swelling in the neck as a possible sign of thyroid cancer and lists hoarseness and trouble swallowing among the others.

Other label warnings describe specific signs:

• Acute pancreatitis: persistent or severe abdominal pain that sometimes spreads to the back, with or without vomiting. Fatal cases have been seen with drugs in this class.
• Gallbladder disease: in adult weight-loss trials, gallstones were reported in 1.6% of people on Wegovy injections versus 0.7% on placebo, and gallbladder inflammation in 0.6% versus 0.2%. The label notes the excess remained after accounting for how much weight people lost.
• Severe gastrointestinal reactions: 4.1% on Wegovy injections versus 0.9% on placebo. The label also warns that fluid loss from ongoing vomiting or diarrhea can lead to kidney injury.

Gray-market GLP-1 products, including research-labeled retatrutide, have no label. The approved drugs' warnings are the closest reference, but they assume a known dose of a pure product.

Melanocortins

Bremelanotide, sold as Vyleesi for low sexual desire in premenopausal women, raises blood pressure after each dose by up to 6 mmHg systolic and 3 mmHg diastolic. The rise peaks 2 to 4 hours after injection and is usually gone within 12 hours. The label contraindicates Vyleesi in uncontrolled hypertension or known cardiovascular disease, which the contraindicated conditions page puts in context. Nausea affected 40% of trial participants, and 8% stopped treatment because of it. Focal hyperpigmentation, darkened patches on areas such as the face or gums, was reported in 1% of people using up to 8 doses a month, but in 38% of people in a separate study who dosed daily for 8 days. It was more likely in people with darker skin and didn't always fade after stopping.

Melanotan II has no label. A 2014 review of 18 clinical trials and 21 case reports found mostly minor trial side effects (nausea and yawning, plus darkening of existing moles), while the case reports included melanoma and a systemic toxic reaction; poor reporting made causality hard to judge. FDA's compounding review adds published case reports of priapism and of posterior reversible encephalopathy syndrome, a form of brain swelling. In a case report in the European Journal of Dermatology, a 24-year-old bodybuilder developed many new moles, and darkening of existing ones, within 24 hours of a single injection.

Injection-site reactions, infection and contamination

Injection-site reactions are common even with pharmaceutical-grade products. On the Egrifta label they affected 25% of people versus 14% on placebo in the first 26 weeks. Vyleesi's trials reported them in 13.2% of participants versus 8.4% on placebo. FDA's figure of about 70% for CJC-1295 is far higher than either.

Infection and contamination are a bigger concern for research products. As of October 2026, Health Canada's April 2026 advisory on unauthorized injectable peptides warns that they can cause infections and allergic reactions. It says they may hold the wrong amount of active ingredient or none at all. Contaminants it names run from heavy metals and solvents to glass or plastic particles and microbes, including endotoxins. It adds that "For Research Use Only" labeling doesn't make these products legal.

MedlinePlus describes skin infection (cellulitis) as redness that keeps spreading and feels warm or tender. Fever with chills often comes with it. It advises contacting a health care provider right away.

Allergic reactions and anaphylaxis

FDA's reviews flag a risk of immune reactions (immunogenicity) for nearly every research peptide they cover, mostly because of aggregation and peptide-related impurities, and its ipamorelin review notes that the risk may be higher with injection under the skin. Hypersensitivity reactions such as hives or rash occurred in 4% of people on Egrifta in trials, and the Wegovy label reports serious reactions including anaphylaxis and angioedema.

The patient sections of both labels describe swelling of the face or throat and trouble breathing as signs of a serious allergic reaction that needs medical help right away. MedlinePlus notes that anaphylaxis symptoms often develop within minutes and classes it as an emergency needing immediate care.

What we still don't know

For unapproved peptides, nobody knows how often these warning signs occur: case reports capture unusual cases, and user reports come from self-selected people posting online. The MK-677 and CJC-1295 trials were small, and neither tested the stacks users commonly describe. A reaction after a gray-market injection may stem from the peptide itself or from a contaminant or wrong dose. Our safety protocols page covers the monitoring approaches people describe.